Livongo, which helps patients manage diabetes and hypertension via connected devices and a cloud based platform, raises $105M Series E at $800M+ valuation
Livongo Health, a startup that develops connected devices and software for patients with diabetes and other chronic conditions …
Context & Ripple Effects
In April 2018, Livongo's $105M Series E at an $800M+ valuation was one of the largest private rounds in connected chronic-care devices, and came amid reports that Livongo, One Medical, and Teladoc had together raised roughly $1.6B in convertible notes within a month. The round funded the device-plus-cloud model for diabetes and hypertension management ahead of the company's push to public markets.
The arc since then validates the bet: Livongo filed for an IPO reporting $32.06M in Q1 2019 revenue against a $14.96M net loss, then closed its first day up 36% at $38.10 for a ~$3.6B valuation, and was ultimately acquired by Teladoc Health in an $18.5B deal.
First-order effects
- Livongo gains the balance sheet to scale its connected-device fleet and cloud platform for diabetes and hypertension patients, positioning it for the IPO filing that followed within fifteen months.
- Investors signal that hardware-plus-software chronic disease management is a fundable category at late-stage scale, not just a consumer gadget niche.
Second-order effects
- Rivals in remote diabetes care accelerate their own fundraising to keep pace — Virta Health raised $65M at a ~$1.1B valuation in late 2020 and a $133M Series E at $2B months later, while Glooko's $100M Series F in 2024 shows the category still drawing nine-figure rounds.
- Telemedicine platforms watching Livongo's growth see remote monitoring as an acquisition target rather than a build-it-yourself project, setting up competitive bidding for the asset.
Third-order effects
- The pattern that ends with Teladoc's $18.5B acquisition of Livongo points toward chronic-care management consolidating into broad telehealth platforms, with standalone device-and-app companies becoming modules inside larger virtual-care stacks.
- If sustained funding for diabetes-focused players like Virta and Glooko continues, the sector splits into platform consolidators on one side and specialized condition-management specialists on the other, with employers and payers as the pricing gatekeepers.
The trend: Connected chronic-disease management is maturing from venture-backed standalone startups into consolidated telehealth platforms, with each funding round raising the bar for who can compete independently.